 | | Vol. 12.00 – 7 January, 2021 |
| |
|
|
| Researchers report on Mammary Tumor Associated RNA 25 (MaTAR25), a nuclear enriched and chromatin associated lncRNA that plays a role in mammary tumor cell proliferation, migration, and invasion, both in vitro and in vivo.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists demonstrated that a switch in ECM composition to be critical for axon regeneration after spinal cord injury and identify the cellular source and components of the growth-promoting lesion ECM.
[Developmental Cell] |
|
|
|
| Investigators showed that healthy donors and cancer patients harbor CD4+ and CD8+ T cells specific for TGFβ-derived epitopes and that cytotoxic T cells with specificity toward TGFβ-derived epitopes were able to recognize and kill cancer cell lines in a TGFβ-dependent manner.
[Cellular & Molecular Immunology] |
|
|
|
| The authors demonstrated both safeties of transplantation of a cultured human autologous dermal fibroblast sheet to lung air leaks.
[npj Regenerative Medicine] |
|
|
|
| Researchers demonstrated that ILB® acts, in part, by downregulating transforming growth factor β signaling genes and by altering gene expression relating to ECM dynamics, leading to tissue remodeling, reduced fibrosis and functional tissue regeneration.
[npj Regenerative Medicine] |
|
|
|
| Investigators explored the pathogenic significance of histamine releasing factor/translationally controlled tumor protein (HRF/TCTP) and evaluated the therapeutic effects of HRF/TCTP blockade in rheumatoid arthritis (RA). HRF/TCTP transgenic and knockdown mice with collagen-induced arthritis were used to determine the experimental phenotypes of RA.
[Experimental and Molecular Medicine] |
|
|
|
| To identify key drivers of metastasis, scientists studied human CCH-OS-D osteocarcinoma cells within a previously described rat acellular lung model that preserved the native lung architecture, ECM, and capillary network.
[Cancer Gene Therapy] |
|
|
|
| Investigators found that a single day of TGF-β1 exposure was sufficient to trigger bone marrow-derived stromal cell chondrogenic differentiation and tissue formation, similar to 21 days of TGF-β1 exposure.
[Communications Biology] |
|
|
|
| The authors proposed the least microenvironmental uncertainty principle that may serve as a generative model of collective migration without precise incorporation of full mechanistic details.
[Scientific Reports] |
|
|
|
|
| Scientists review recent advances in identifying the stroma-dependent mechanisms that regulate cancer-associated inflammation and antitumor immunity, in particular, the interactions between fibroblasts and immune cells.
[eLife] |
|
|
|
| The authors provide the first comprehensive overview of how electrospun fiber alignment, diameter, surface nanotopography, surface functionalization, and therapeutic delivery affect Schwann cells in the peripheral nervous system and astrocytes, oligodendrocytes, and microglia in the central nervous system
[Bioengineering] |
|
|
|
| Investigators define modes of metabolic regulation and review how distinct cell types contribute to the metabolite composition of the tumor microenvironment.
[Nature Metabolism] |
|
|
|
|
| Landos Biopharma announced positive results from a first-in-patients 12-week Phase II proof-of-concept trial of BT-11, a novel, orally administered, gut-restricted LANCL2 modulator in patients with mild to moderate ulcerative colitis. By activating the LANCL2 pathway and modulating the interactions between immunological and metabolic signals in immune cells, BT-11 is designed to create a favorable regulatory microenvironment in the gut.
[Landos Biopharma] |
|
|
|
| Apollomics, Inc. and GlycoMimetics announced APL-106 has been granted Breakthrough Therapy Designation from the China National Medical Products Administration Center for Drug Evaluation for the treatment of relapsed/refractory acute myeloid leukemia. The product is designed to block E-selectin from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment.
[Apollomics, Inc.] |
|
|
|
|
|
|
|
| | STEMCELL Technologies, Inc. – Burnaby, British Columbia, Canada |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Duke University – Durham, North Carolina, United States |
|
|
|
| | Karlsruhe Institute of Technology – Karlsruhe, Baden-Württemberg, Germany |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
